BioCentury
ARTICLE | Clinical News

Procept begins Phase II

February 11, 2000 8:00 AM UTC

Procept ( Cambridge, Mass.), a subsidiary of HeavenlyDoor.com (HVDC), began a U.S. Phase II trial of its 0-6-Benzylguanine chemosensitizing agent in combination with carmustine to treat cerebral anapl...